A nation-wide analysis of venous thromboembolism in 497,180 cancer patients with the development and validation of a risk-stratification scoring system

Thrombosis and Haemostasis

Volumn 108, Issue 2, 2012, Pages 225-235

  Yu, Yuan Bin ^a,b   Gau, Jyh Pyng ^a,b   Liu, Chun Yu ^a,b   Yang, Muh Hwa ^a,b   Chiang, Shu Chiung ^b   Hsu, Hui Chi ^a,b   Hong, Ying Chung ^a,b   Hsiao, Liang Tsai ^a,b   Liu, Jin Hwang ^a,b   Chiou, Tzeon Jye ^a,b   Chen, Po Min ^a,b   Lee, Tzong Shyuan ^a   Chou, Li Fang ^c   Tzeng, Cheng Hwai ^a,b   Chen, Tzeng Ji ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL CHENGCHI UNIVERSITY   (Taiwan)

Author keywords

Cancer; Epidemiology; Scoring system; Venous thromboembolism

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CHILD; COMORBIDITY; DEATH; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; GENDER; GENITAL TRACT TUMOR; HUMAN; INCIDENCE; INFANT; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; METASTASIS; MYELOMA; NEWBORN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; SARCOMA; SCORING SYSTEM; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; RISK; RISK FACTORS; TAIWAN; TIME FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84864343340     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-01-0010     Document Type: Article

References (44)

1. Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162: 1245-1248.
2. Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. J Am Med Assoc 2005; 293: 715-722.
3. Stein PD, Beemath A, Meyers FA, et al. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006; 119: 60-68.
4. Gomes MP, Deitcher SR. Diagnosis of venous thromboembolic disease in cancer patients. Oncology (Williston Park) 2003; 17: 126-135, 139-144.
5. Ogren M, Bergqvist D, Wahlander K, et al. Trousseau's syndrome-what is the evidence? A population-based autopsy study. Thromb Haemost 2006; 95: 541-545.
6. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002; 87: 575-579.
7. Thodiyil PA, Kakkar AK. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost 2002; 87: 1076-1077.
8. Ng HJ, Lee LH. Trends in prevalence of deep venous thrombosis among hospitalised patients in an Asian institution. Thromb Haemost 2009; 101: 1095-1099.
9. White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 1998; 128: 737-740.
10. Klatsky AL, Armstrong MA, Poggi J. Risk of pulmonary embolism and/or deep venous thrombosis in Asian-Americans. Am J Cardiol 2000; 85: 1334-1337.
11. Stein PD, Kayali F, Olson RE, et al. Pulmonary thromboembolism in Asians/ Pacific Islanders in the United States: analysis of data from the National Hospital Discharge Survey and the United States Bureau of the Census. Am J Med 2004; 116: 435-442.
12. Mannucci PM. Thrombosis and bleeding disorders outside Western countries. J Thromb Haemost 2007; 5 (Suppl 1): 68-72.
13. Lee CH, Lin LJ, Cheng CL, et al. Incidence and cumulative recurrence rates of venous thromboembolism in the Taiwanese population. J Thromb Haemost 2010; 8: 1515-1523.
14. Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166: 458-464.
15. Ho CH, Chau WK, Hsu HC, et al. Causes of venous thrombosis in fifty Chinese patients. Am J Hematol 2000; 63: 74-78.
16. Shen MC, Lin JS, Tsay W. Protein C and protein S deficiencies are the most important risk factors associated with thrombosis in Chinese venous thrombophilic patients in Taiwan. Thromb Res 2000; 99: 447-452.
17. Peng YY, Jeng JS, Shen MC, et al. Aetiologies and prognosis of Chinese patients with deep vein thrombosis of the lower extremities. QJM 1998; 91: 681-686.
18. Kroger K, Weiland D, Ose C, et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 2006; 17: 297-303.
19. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-4907.
20. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 2009; 27: 4839-4847.
21. Connolly GC, Khorana AA. Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thromb Res 2010; 125 (Suppl 2): S1-7.
22. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505.
23. Khorana AA, Streiff MB, Farge D, et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 2009; 27: 4919-4926.
24. Mandala M, Falanga A, Roila F. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management. Ann Oncol 2010; 21 (Suppl 5): v274-276.
25. Chen YC, Yeh HY, Wu JC, et al. Taiwan's National Health Insurance Research Database: administrative health care database as study object in bibliometrics. Scientometrics 2010; 86: 365-380.
26. Cheng CL, Kao YH, Lin SJ, et al. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 2011; 20: 236-242.
27. Tamariz L, Harkins T, Nair V. A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data. Pharmacoepidemiol Drug Saf 2012; 21 (Suppl 1): 154-162.
28. Anderson FA, Jr., Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151: 933-938.
29. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-593.
30. Spencer FA, Emery C, Lessard D, et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006; 21: 722-727.
31. Lee CH, Cheng CL, Chang CH, et al. Universal pharmacological thromboprophylaxis for total knee arthroplasty may not be necessary in low-risk populations: a nationwide study in Taiwan. J Thromb Haemost 2012; 10: 56-63.
32. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006; 24: 484-490.
33. Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007; 110: 2339-2346.
34. Blom JW, Vanderschoot JP, Oostindier MJ, et al. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006; 4: 529-535.
35. Mandala M, Barni S, Floriani I, et al. Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings. Eur J Cancer 2009; 45: 65-73.
36. Pritchard KI, Paterson AH, Paul NA, et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 1996; 14: 2731-2737.
37. Blanco-Molina A, Trujillo-Santos J, Tirado R, et al. Venous thromboembolism in women using hormonal contraceptives. Findings from the RIETE Registry. Thromb Haemost 2009; 101: 478-482.
38. Potosky AL, Saxman S, Wallace RB, et al. Population variations in the initial treatment of non-small-cell lung cancer. J Clin Oncol 2004; 22: 3261-3268.
39. Blom JW, Osanto S, Rosendaal FR. High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients. Eur J Cancer 2006; 42: 410-414.
40. Mandala M, Reni M, Cascinu S, et al. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol 2007; 18: 1660-1665.
41. Menapace LA, Peterson DR, Berry A, et al. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost 2011; 106: 371-378.
42. Oh SY, Kim JH, Lee KW, et al. Venous thromboembolism in patients with pancreatic adenocarcinoma: lower incidence in Asian ethnicity. Thromb Res 2008; 122: 485-490.
43. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003; 107: I17-21.
44. Lee KW, Bang SM, Kim S, et al. The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer. J Thromb Haemost 2010; 8: 540-547.